Giovanni Mariggi

Giovanni is a co-founder and Partner at Medicxi. Prior to Medicxi, Giovanni was a Principal at Index Ventures. He led Medicxi’s investment in ViceBio (acquired by Sanofi), Aura Biosciences (NASDAQ:AURA), New Amsterdam (NASDAQ:NAMS), Curevo and Abivax (Euronext:ABVX). 

Giovanni currently serves on the boards of a number of portfolio companies, including ForeBio, Vaderis Therapeutics (Chair), Aura Biosciences, Breakpoint Therapeutics and Curevo.  

Giovanni received a BSc in Biochemistry from Imperial College London and a PhD in Biochemistry and Molecular Biology from University College London.